Petty Atmadja

Petty Atmadja

Auto-generated profile, based on publicly available information

Petty Atmadja

Affiliation Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Central Hospital, Bandung, Indonesia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AIAgnes Rengga Indrati
Agnes Rengga Indrati
ASAnton Sumarpo
Anton Sumarpo
PAPetty Atmadja
Petty Atmadja
RWRositha Ratna Wisesa
Rositha Ratna Wisesa
MGMohammad Ghozali
Mohammad Ghozali
BSBudi Setiabudiawan
Budi Setiabudiawan
Background: Interferon gamma release assays (IGRAs) are widely used to determine latent tuberculosis infection status. However, its pregnancy-affected performance and cost-expensive nature warrants for different alternatives for pregnant women. This study aims to evaluate the diagnostic performance of several alternative cytokines, including interleukin 2 (IL-2), interleukin 10 (IL-10), and interferon gamma-induced protein 10 (IP-10) to identify latent tuberculosis status in pregnant women. Materials and methods: 123 pregnant womens were recruited for this study. The IGRA status was determined by using QuantiFERON Gold In-Tube. Meanwhile, we measured the level IL-2, IL-10, and IP-10 by using sandwich-microELISA method. We performed normality and comparison test by SPSS. In addition, receiver-operator characteristic (ROC) analyses and the optimal cutoff scores were identified using the EasyROC webtool. Results: We showed that IL-2, IL-10, and IP-10 were able to discriminate between IGRA-negative and IGRA-positive pregnant women. Moreover, IP-10 showed the highest discriminatory and diagnostic performance when compared to IL-2 and IL-10 with area under the curve (AUC) of 0.96 and cutoff point of 649.65 pg/mL. Conclusions: Our study showed that IP-10 can be considered as a promising alternative biomarker for IGRAs to diagnose LTBI in pregnant women.